List of Yonsa drug patents

Yonsa is owned by Sun Pharm.

Yonsa contains Abiraterone Acetate.

Yonsa has a total of 2 drug patents out of which 0 drug patents have expired.

Yonsa was authorised for market use on 22 May, 2018.

Yonsa is available in tablet;oral dosage forms.

Yonsa can be used as use in combination with methylprednisolone for the treatment of patients with prostate cancer.

The generics of Yonsa are possible to be released after 20 May, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9889144 SUN PHARM Abiraterone acetate formulation and methods of use
Mar, 2034

(10 years from now)

US10292990 SUN PHARM Abiraterone steroid formulation
May, 2034

(11 years from now)

Drugs and Companies using ABIRATERONE ACETATE ingredient

Market Authorisation Date: 22 May, 2018

Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer

Dosage: TABLET;ORAL

How can I launch a generic of YONSA before it's patent expiration?
More Information on Dosage

YONSA family patents

14

United States

4

Korea, Republic of

4

Japan

3

Australia

3

Singapore

3

China

3

European Union

2

Israel

2

Mexico

2

Hong Kong

2

Morocco

2

Brazil

2

Taiwan, Province of China

2

Canada

2

Tunisia

1

South Africa

1

Russia

1

Philippines

1

Moldova, Republic of

1

Argentina

1

Colombia

1

Spain

1

Poland

1

Chile

EA

1

EA

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic